Peptide ligands in antibacterial drug discovery: Use as inhibitors in target validation and target-based screening

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 4, 2002, Pages 507-516

  Lapan, Kirsty A ^a   Chapple, Joanne P ^a   Galcheva Gargova, Zoya ^a   Yang, Min ^a   Tao, Jianshi ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Antibacterial; Drug resistance; High throughput screening; Peptide; Target validation; VITA

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BACITRACIN; CEFALOTIN; CHLORAMPHENICOL; CYCLOSERINE; DALFOPRISTIN; DAPTOMYCIN; DNA; DOXYCYCLINE; FOSFOMYCIN; IMIPENEM; LIGAND; LINEZOLID; MEMBRANE PROTEIN; NISIN; PENICILLIN G; PEPTIDE DERIVATIVE; POLYMYXIN; PROTEIN DERIVATIVE; PSEUDOMONIC ACID; QUINUPRISTIN; RNA; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GENOMICS; HELICOBACTER PYLORI; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; GENOME, BACTERIAL; GENOMICS; HUMANS; LIGANDS; MICE; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0036051908     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.4.507     Document Type: Article

References (73)

1. WHO report on Infectious Diseases: Removing Obstacles to Healthy Development
2. Antimicrobial resistance in the intensive care unit
3. Increasing prevalence of antimicrobial resistance in intensive care units
4. Antimicrobial-drug resistance
5. The crisis in antibiotic resistance
6. Trends in infectious diseases mortality in the United States
7. Emergent antibiotic resistance: Health risks and economic impact
8. Mechanism-based screens in the discovery of chemotherapeutic antibacterials
9. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics
10. Ciprofloxacin in combination with other antimicrobials
11. Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance
12. Antibiotic synergism and antimicrobial combinations in clinical infections
13. The challenge of antibiotic resistance
14. Antimicrobial resistance in intensive care units
15. Origins and evolution of bacterial resistance
16. Molecular mechanisms that confer antibacterial drug resistance
17. Sequencing and analysis of bacterial genomes
18. The impact of microbial genomics on antimicrobial drug development
19. Analysis of the genetic diversity of Helicobacter pylori: The tale of two genomes
20. Helicobacter pylori
21. Metabolic databases
22. GcpE is involved in the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in Escherichia coli
23. The minimal cell genome: 'On being the right size'
24. A minimal gene set for cellular life derived by comparison of complete bacterial genomes
25. Common themes in microbial pathogenicity
26. Pathogenicity islands: Bacterial evolution in quantum leaps
27. Microbial pathogenesis: Genomics and beyond
28. A genome-based approach for the identification of essential bacterial genes
29. The Escherichia coli genome sequence: The end of an era or the start of the FUN?
30. The complete genome sequence of Escherichia coli K-12
31. Methods for generating precise deletions and insertions in the genome of wild-type Escherichia coli; application to open reading frame characterization
32. A vector for systematic gene inactivation in Bacillus subtilis
33. Genetic analysis of temperature-sensitive lethal mutants of Salmonella typhimurium
34. Antisense RNA: Its functions and applications in gene regulation-a review
35. Systematic identification of essential genes by in vitro mariner mutagenesis
36. Transposon-based approaches to identify essential bacterial genes
37. Global transposon mutagenesis and a minimal Mycoplasma genome
38. Use of representational difference analysis to identify genomic differences between pathogenic strains of Vibrio cholerae
39. Identification of differential gene expression by high throughput analysis
40. Bacterial genetics by flow cytometry: Rapid isolation of Salmonella typhimurium acid-inducible promoters by differential fluorescence induction
41. Identification of novel staphylococcal virulence genes by in vivo expression technology
42. Identification of Staphylococcus aureus virulence genes in a murine model of bacteraemia using signature-tagged mutagenesis
43. New targets and strategies for the development of antibacterial agents
44. Method for identifying validated target and assay combinations for drug development
45. Synthetic combinatorial libraries: Novel discovery strategy for identification of antimicrobial agents
46. Generation and use of nonsupport-bound peptide and peptidomimetic combinatorial libraries
47. Ribosome display: An in vitro method for selection and evolution of antibodies from libraries
48. Peptides on phage: A vast library of peptides for identifying ligands
49. Displaying libraries of conformationally constrained peptides on the surface of Escherichia coli as flagellin fusions
50. Libraries of peptides and proteins displayed on filamentous phage
51. Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries
52. Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements
53. Blue/white screening of recombinant plasmids in Gram-positive bacteria by interruption of alkaline phosphatase gene (phoZ) expression
54. Regulable gene expression in Gram-positive bacteria
55. Homology of the TetM with translational elongation factors implications for potential modes of tetM-conferred tetracycline resistance
56. Drug target validation: Lethal infection blocked by inducible peptide./
57. Evidence that tetracycline analogs whose primary target is not the bacterial ribosome cause lysis of Escherichia coli
58. Molecular basis of tetracycline action: Identification of analogs whose primary target is not the bacterial ribosome
59. Isolation of peptide aptamers that inhibit intracellular process
60. Application of VITA™ technology to antibacterial drug discovery
61. DNA microarray technology and antimicrobial drug discovery
62. Fluorescence polarization: An analytical tool for immunoassay and drug discovery
63. Ultrasensitive bioanalytical assays using time-resolved fluorescence detection
64. Time-resolved fluorescence spectroscopy
65. Single-molecule fluorescence resonance energy transfer
66. High-throughput screening strategies for cardiac ion channels
67. Ratiometric single-molecule studies of freely diffusing biomolecules
68. Imaging of single molecule diffusion
69. Methods of screening combinatorial libraries using immobilized or restrained receptors
70. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach
71. Recent trends in protein biochip technology
72. New approaches to rational drug design
73. Inhibitors of aminoacyl-tRNA synthetases as novel anti-infectives